Literature DB >> 33255794

Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.

Shen Li1, Antonio Saviano2, Derek J Erstad1, Yujin Hoshida3, Bryan C Fuchs1, Thomas Baumert2, Kenneth K Tanabe1.   

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality globally. Given the limited therapeutic efficacy in advanced HCC, prevention of HCC carcinogenesis could serve as an effective strategy. Patients with chronic fibrosis due to viral or metabolic etiologies are at a high risk of developing HCC. Primary prevention seeks to eliminate cancer predisposing risk factors while tertiary prevention aims to prevent HCC recurrence. Secondary prevention targets patients with baseline chronic liver disease. Various epidemiological and experimental studies have identified candidates for secondary prevention-both etiology-specific and generic prevention strategies-including statins, aspirin, and anti-diabetic drugs. The introduction of multi-cell based omics analysis along with better characterization of the hepatic microenvironment will further facilitate the identification of targets for prevention. In this review, we will summarize HCC risk factors, pathogenesis, and discuss strategies of HCC prevention. We will focus on secondary prevention and also discuss current challenges in translating experimental work into clinical practice.

Entities:  

Keywords:  NASH; chemoprevention; hepatitis; hepatocellular carcinoma

Year:  2020        PMID: 33255794      PMCID: PMC7760293          DOI: 10.3390/jcm9123817

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  275 in total

1.  Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.

Authors:  Chin-Hsiao Tseng
Journal:  Liver Int       Date:  2018-06-29       Impact factor: 5.828

2.  Activation of cultured rat hepatic stellate cells by tumoral hepatocytes.

Authors:  S Faouzi; S Lepreux; C Bedin; L Dubuisson; C Balabaud; P Bioulac-Sage; A Desmoulière; J Rosenbaum
Journal:  Lab Invest       Date:  1999-04       Impact factor: 5.662

3.  Gender disparity of hepatocellular carcinoma: the roles of sex hormones.

Authors:  Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

Review 4.  Hepatocellular carcinoma in the setting of alcohol-related liver disease.

Authors:  Nathalie Ganne-Carrié; Pierre Nahon
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

Review 5.  Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.

Authors:  Mandeep Kumar Singh; Bhrigu Kumar Das; Sandeep Choudhary; Deepak Gupta; Umesh K Patil
Journal:  Biomed Pharmacother       Date:  2018-07-14       Impact factor: 6.529

6.  Vitamin D3 upregulated protein 1 suppresses TNF-α-induced NF-κB activation in hepatocarcinogenesis.

Authors:  Hyo-Jung Kwon; Young-Suk Won; Hyun-Woo Suh; Jun-Ho Jeon; Yan Shao; Suk-Ran Yoon; Jin-Woong Chung; Tae-Don Kim; Hwan-Mook Kim; Ki-Hoan Nam; Won-Kee Yoon; Dae-Ghon Kim; Jeong-Hwan Kim; Young-Sung Kim; Dae-Yong Kim; Hyoung-Chin Kim; Inpyo Choi
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

7.  Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Authors:  Charlotte E Costentin; Richard Layese; Valérie Bourcier; Carole Cagnot; Patrick Marcellin; Dominique Guyader; Stanislas Pol; Dominique Larrey; Victor De Lédinghen; Denis Ouzan; Fabien Zoulim; Dominique Roulot; Albert Tran; Jean-Pierre Bronowicki; Jean-Pierre Zarski; Ghassan Riachi; Paul Calès; Jean-Marie Péron; Laurent Alric; Marc Bourlière; Philippe Mathurin; Jean-Frédéric Blanc; Armand Abergel; Lawrence Serfaty; Ariane Mallat; Jean-Didier Grangé; Pierre Attali; Yannick Bacq; Claire Wartelle; Thông Dao; Dominique Thabut; Christophe Pilette; Christine Silvain; Christos Christidis; Eric Nguyen-Khac; Brigitte Bernard-Chabert; David Zucman; Vincent Di Martino; Angela Sutton; Eric Letouzé; Sandrine Imbeaud; Jessica Zucman-Rossi; Etienne Audureau; Françoise Roudot-Thoraval; Pierre Nahon
Journal:  Gastroenterology       Date:  2018-05-03       Impact factor: 22.682

8.  Look back in anger - what clinical studies tell us about preclinical work.

Authors:  Thomas Hartung
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.

Authors:  Frank E Uschner; Ganesh Ranabhat; Steve S Choi; Michaela Granzow; Sabine Klein; Robert Schierwagen; Esther Raskopf; Sebastian Gautsch; Peter F M van der Ven; Dieter O Fürst; Christian P Strassburg; Tilman Sauerbruch; Anna Mae Diehl; Jonel Trebicka
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

View more
  12 in total

1.  The expression and prognostic value of REXO4 in hepatocellular carcinoma.

Authors:  Weipeng Chen; Cheng Gao; Jianbo Shen; Lanqing Yao; Xiaoliang Liang; Zhong Chen
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics.

Authors:  Cheng Gao; Jianbo Shen; Weipeng Chen; Lanqing Yao; Xiaoliang Liang; Renfei Zhu; Zhong Chen
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  Hepatitis B Core Antibody Positivity Associated with Increased Risk of Liver Cancer in Patients with Chronic Hepatitis C: Analysis of a Large Patient Cohort in Hawai'i.

Authors:  Olivia A Collis; Patrycja A Ashley; Li-Hsieh Chen; Kathryn L Pedula; Shelley M Miyashiro; Shellie K Yamashita
Journal:  Hawaii J Health Soc Welf       Date:  2022-05

Review 4.  Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.

Authors:  Haichuan Wang; Xin Chen; Diego F Calvisi
Journal:  Expert Opin Ther Targets       Date:  2021-09-11       Impact factor: 6.797

5.  Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial.

Authors:  Antonio Saviano; François Habersetzer; Joachim Lupberger; Pauline Simo-Noumbissie; Catherine Schuster; Michel Doffoël; Catherine Schmidt-Mutter; Thomas F Baumert
Journal:  Clin Transl Gastroenterol       Date:  2022-06-01       Impact factor: 4.396

6.  Transcriptome Analysis Reveals the Anti-cancerous Mechanism of Licochalcone A on Human Hepatoma Cell HepG2.

Authors:  Jun Wang; Bo Wei; Kiran Thakur; Chu-Yan Wang; Ke-Xin Li; Zhao-Jun Wei
Journal:  Front Nutr       Date:  2021-12-20

7.  Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.

Authors:  Joachim Lupberger; Thomas F Baumert
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

8.  Increased risk of hepatocellular carcinoma in patients with traumatic liver injury: Real-world data from a nationwide population-based study.

Authors:  Yen-Ju Chen; Chih-Jung Shen; Shao-Hua Yu; Cheng-Li Lin; Hong-Mo Shih
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

Review 9.  Liquorice for pain?

Authors:  Rae F Bell; Vânia M Moreira; Eija A Kalso; Jari Yli-Kauhaluoma
Journal:  Ther Adv Psychopharmacol       Date:  2021-07-16

10.  Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Kazusuke Matsumoto; Junya Suzuki; Koji Murata; Yuki Tsuji; Keisuke Nakanishi; Kosuke Kaji; Mitsuteru Kitade; Ryuichi Noguchi; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.